After enduring operating losses in 2022, biote Corp. achieved a financial turnaround with 12.5% year-over-year operating income growth and over sevenfold net income increase in 2025, underpinned by its integrated Biote Method platform that combines practitioner certification, specialized software, and marketing support for hormone optimization. Despite ongoing legal disputes and tariff challenges increasing supply chain costs, the company maintains compliance with debt covenants and exhibits robust operating cash flow generation. Capital expenditures have been prudently scaled back following earlier investments, while dividends and share buybacks have been moderated to preserve liquidity amid operational uncertainties.